56 unknown, 4 completed, 1 active not recruiting, 1 not yet recruiting. 13 Phase 2, 5 Phase 3, 3 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Unknown 11, Completed 2 |
| Phase 3 | 5 | Unknown 5 |
| Not applicable | 3 | Unknown 3 |
| Phase 4 | 1 | Unknown 1 |
Follow Lei Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cervical Cytology DNA Methylation for Endometrial Cancer Screening CDO1 and CELF4 gene methylation - Endometrial Cancer, DNA Methylation | Active not recruiting | Lei Li | 30000 | 2025-12-12 | 2026-10-15 | |
| Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence Ovarian Cancer | Not yet recruiting | Lei Li | 509 | 2024-10-01 | 2024-08-16 | |
| Cervical Cytology DNA Methylation for Cervical Cancer Screening human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m) - Cervical Cancer, DNA Methylation | Unknown | Lei Li | 30000 | 2024-09-01 | 2024-08-19 | |
| A Multicenter Randomized Controlled Study of Photoelectric Detection in Cervical Cancer Screening Detection of Cervical Lesions by Fluorescence Photoelectric Image - Uterine Cervical Cancer, Cervical Intraepithelial Neoplasia | Not applicable | Unknown | Lei Li | 4200 | 2024-08-01 | 2024-08-15 |
| A Multicenter Real-world Study of Screening of Cervical Cancer Based on Photoelectric Detection Detection of Cervical Lesions by Fluorescence Photoelectric Image - Uterine Cervical Cancer, High Grade Squamous Intraepithelial Lesions | Unknown | Lei Li | 20000 | 2024-07-01 | 2024-07-03 | |
| ctDNA Methylation for Epithelial Ovarian Cancer CDO1 and HOXA9 methylation assay - Epithelial Ovarian Cancer, Circulating Tumor DNA | Unknown | Lei Li | 5000 | 2023-03-24 | 2023-04-06 | |
| ctDNA Methylation for Detecting Ovarian Cancer Methylation assay - Epithelial Ovarian Cancer, Circulating Tumor DNA | Unknown | Lei Li | 1400 | 2023-03-24 | 2023-04-06 | |
| HRD Status Reference Standard Based on WGS PARPi - Ovarian Cancer | Completed | Lei Li | 100 | 2022-12-30 | 2024-07-08 | |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Niraparib plus anlotinib - Ovarian Carcinoma, Survival Outcomes | Phase 2 | Unknown | Lei Li | 36 | 2022-03-27 | 2022-04-13 |
| Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer Albumin-bound paclitaxel and bevacizumab - Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 2 | Unknown | Lei Li | 50 | 2022-03-27 | 2022-04-04 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Donafenib for Recurrent Cervical Cancer Donafenib combined with paclitaxel and platinum ± PD-1 antibody - Targeted Therapy, Chemotherapy | Phase 2 | Unknown | Lei Li | 20 | 2022-03-27 | 2022-04-04 |
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Camrelizumab plus Concurrent chemoradiotherapy - Cervical Carcinoma, Chemoradiotherapy | Phase 2 | Unknown | Lei Li | 92 | 2022-03-27 | 2022-04-13 |
| Prognosis of Low-grade Endometrial Stromal Sarcoma Surgical treatment with and without fertility-sparing procedures - Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis), Fertility-sparing Surgery | Unknown | Lei Li | 1000 | 2022-03-26 | 2022-04-04 | |
| HRD and Resistance to PAPPi in EOC Patients Testing of homologous recombination deficiency - Epithelial Ovarian Cancer, Homologous Recombination Deficiency | Unknown | Lei Li | 400 | 2022-03-26 | 2022-04-04 | |
| Chromosomal Instability in Ovarian Cancer Testing for chromosomal instability (CIN) - Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma | Unknown | Lei Li | 300 | 2022-03-26 | 2022-04-04 | |
| PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer Radiotherapy for targeted lesions and PD-1 antibody - Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody | Unknown | Lei Li | 20 | 2022-03-26 | 2022-04-11 | |
| Cervical Cancer Screening Strategies Cervical Cancer, Cervical Intraepithelial Neoplasia | Unknown | Lei Li | 10000 | 2022-03-19 | 2022-04-04 | |
| Host DNA Methylation for Endometrial Cancer Screening DNA methylation testing - Cancer Screening, Endometrial Cancer | Unknown | Lei Li | 10000 | 2022-03-13 | 2022-03-22 | |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 122 | 2022-03-13 | 2022-03-22 |
Showing 20 of 62. Sign in to see all of them.
Uterine Cervical Neoplasms (22) · Carcinoma, Ovarian Epithelial (13) · Endometrial Neoplasms (8) · Ovarian Neoplasms (7) · Uterine Cervical Dysplasia (5) · Squamous Intraepithelial Lesions (4) · Colorectal Neoplasms, Hereditary Nonpolyposis (3) · Microsatellite Instability (3) · Papillomavirus Infections (3) · Adenomyosis (2) · Carcinogenesis (2) · Disease (2) · Febrile Neutropenia (2) · Pelvic Floor Disorders (2) · Recurrence (2)
Albumin-Bound Paclitaxel (3) · Death Domain (3) · Radiotherapy (3) · Base Sequence (2) · Chemoradiotherapy (2) · DNA Methylation (2) · Drug Therapy (2) · Bevacizumab (1) · Exome Sequencing (1) · Genetic Profile (1) · Microbiota (1) · Paclitaxel (1) · RNA, Long Noncoding (1) · Salpingo-oophorectomy (1) · Surgical Procedures, Operative (1)
China (62)
PMID 29941707, PMID 30759291, PMID 30833442, PMID 31307542, PMID 31362966, PMID 31467066, PMID 32502439, PMID 32819996, PMID 33317612, PMID 34395457, PMID 39603822, PMID 39696092